| Year |
Citation |
Score |
| 2023 |
Chang YS, Gills JJ, Kawabata S, Onozawa M, Della Gatta G, Ferrando AA, Aplan PD, Dennis PA. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia. International Journal of Oncology. 63. PMID 37800623 DOI: 10.3892/ijo.2023.5576 |
0.338 |
|
| 2021 |
Ouwens M, Darilay A, Zhang Y, Mukhopadhyay P, Mann H, Ryan J, Dennis PA. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research, Clinical and Experimental. 95: 100640. PMID 34484473 DOI: 10.1016/j.curtheres.2021.100640 |
0.393 |
|
| 2021 |
Socinski MA, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray JE, Park K, Vincent M, Mann H, Newton M, Dennis PA, Antonia SJ. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer. PMID 34294595 DOI: 10.1016/j.cllc.2021.05.009 |
0.332 |
|
| 2021 |
Kawabata S, Connis N, Gills JJ, Hann CL, Dennis PA. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. Anticancer Research. 41: 91-99. PMID 33419802 DOI: 10.21873/anticanres.14754 |
0.475 |
|
| 2021 |
Lopiccolo J, Kawabata S, Gills JJ, Dennis PA. Combining Nelfinavir With Chloroquine Inhibits Growth of Human Lung Cancer Xenograft Tumors. In Vivo (Athens, Greece). 35: 141-145. PMID 33402459 DOI: 10.21873/invivo.12241 |
0.371 |
|
| 2019 |
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, ... ... Dennis PA, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet. Oncology. PMID 31601496 DOI: 10.1016/S1470-2045(19)30519-4 |
0.366 |
|
| 2019 |
Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, ... ... Dennis PA, et al. A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research. 8: 247-257. PMID 31367538 DOI: 10.21037/Tlcr.2019.04.19 |
0.479 |
|
| 2019 |
Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, Gupta A, Dennis PA, Ye J, Mukhopadhyay P, Higgs BW, et al. Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer. PMID 31327642 DOI: 10.1016/j.cllc.2019.06.020 |
0.359 |
|
| 2019 |
Raben D, Rimner A, Senan S, Broadhurst H, Pellas T, Dennis P, Faivre-Finn C. Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC) International Journal of Radiation Oncology*Biology*Physics. 105: 683. DOI: 10.1016/j.ijrobp.2019.08.034 |
0.382 |
|
| 2018 |
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis PA, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England Journal of Medicine. PMID 30280658 DOI: 10.1056/NEJMoa1809697 |
0.328 |
|
| 2018 |
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, ... ... Dennis PA, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet. Oncology. PMID 29545095 DOI: 10.1016/S1470-2045(18)30144-X |
0.396 |
|
| 2018 |
Rydén A, Ollis S, Love E, Shields A, Jiang H, Dennis P. 80P Understanding the patient perspective of small cell lung cancer (SCLC) Journal of Thoracic Oncology. 13: S44. DOI: 10.1016/S1556-0864(18)30355-1 |
0.393 |
|
| 2017 |
Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget. 8: 87044-87053. PMID 29152062 DOI: 10.18632/oncotarget.19667 |
0.393 |
|
| 2017 |
Antonia S, Villegas A, Daniel D, Baz DV, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis P, et al. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: 1314-1315. DOI: 10.1016/J.IJROBP.2017.09.011 |
0.361 |
|
| 2015 |
Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer. Cancer Research. PMID 26637667 DOI: 10.1158/0008-5472.Can-14-3362 |
0.355 |
|
| 2014 |
Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Reports. 7: 1824-32. PMID 24931608 DOI: 10.1016/J.Celrep.2014.05.039 |
0.447 |
|
| 2014 |
Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (Amsterdam, Netherlands). 85: 1-6. PMID 24746758 DOI: 10.1016/j.lungcan.2014.03.021 |
0.397 |
|
| 2014 |
Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5: 1392-433. PMID 24722523 DOI: 10.18632/Oncotarget.1891 |
0.432 |
|
| 2014 |
Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget. 5: 1062-70. PMID 24658085 DOI: 10.18632/oncotarget.1760 |
0.548 |
|
| 2013 |
Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prevention Research (Philadelphia, Pa.). 6: 801-10. PMID 23771523 DOI: 10.1158/1940-6207.Capr-13-0058-T |
0.396 |
|
| 2013 |
Lastwika K, Wilson W, Dennis PA. Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC. Cancer Research. 73: 4981-4981. DOI: 10.1158/1538-7445.Am2013-4981 |
0.319 |
|
| 2013 |
Kitagawa H, Dallos M, Quinn B, Kunnumakkara A, Dogan I, Hollander CM, Dennis PA. Abstract 2269: Metformin prolongs survival in a K-rasLA2 lung cancer mouse model by inhibiting cancer stem cells and tumor growth. Cancer Research. 73: 2269-2269. DOI: 10.1158/1538-7445.Am2013-2269 |
0.403 |
|
| 2012 |
Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W, Hollander MC, Dennis PA. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death & Disease. 3: e353. PMID 22825471 DOI: 10.1038/cddis.2012.87 |
0.357 |
|
| 2012 |
Gills JJ, Zhang C, Abu-Asab MS, Castillo SS, Marceau C, LoPiccolo J, Kozikowski AP, Tsokos M, Goldkorn T, Dennis PA. Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine Cell Death and Disease. 3. PMID 22764099 DOI: 10.1038/Cddis.2012.72 |
0.412 |
|
| 2012 |
West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. Plos One. 7: e31906. PMID 22363766 DOI: 10.1371/Journal.Pone.0031906 |
0.396 |
|
| 2012 |
Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Gills JJ, Hollander MC, Dennis PA. Abstract PR-01: Systemic inhibition of receptor tyrosine kinase signaling by metformin Cancer Prevention Research. 5: PR-01-PR-01. DOI: 10.1158/1940-6207.Prev-12-Pr-01 |
0.396 |
|
| 2011 |
Maier CR, Hollander MC, Hobbs EA, Dogan I, Linnoila RI, Dennis PA. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 1743-51. PMID 22027685 DOI: 10.1158/1940-6207.CAPR-11-0365 |
0.409 |
|
| 2011 |
Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. Plos One. 6: e23849. PMID 21887332 DOI: 10.1371/journal.pone.0023849 |
0.552 |
|
| 2011 |
Hollander MC, Zhou X, Maier CR, Patterson AD, Ding X, Dennis PA. A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis. 32: 1279-84. PMID 21625009 DOI: 10.1093/Carcin/Bgr097 |
0.388 |
|
| 2011 |
Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Molecular Cancer Therapeutics. 10: 1137-48. PMID 21551261 DOI: 10.1158/1535-7163.Mct-10-1028 |
0.464 |
|
| 2011 |
Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene. 30: 1812-21. PMID 21242979 DOI: 10.1038/onc.2010.556 |
0.409 |
|
| 2011 |
Gills JJ, Zhang C, Abu-Asab MS, Castillo SS, Marceau C, Kozikowski A, Tsokos M, Goldkorn T, Dennis PA. Abstract 960: Ceramide-dependent release of nanovesicles is a class effect oflipid-based Akt inhibitors Cancer Research. 71: 960-960. DOI: 10.1158/1538-7445.Am2011-960 |
0.348 |
|
| 2011 |
Kawabata S, Mercado J, Hollander MC, Wilson W, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib Cancer Research. 71: 2836-2836. DOI: 10.1158/1538-7445.Am2011-2836 |
0.49 |
|
| 2011 |
Kawabata S, Hollander MC, Munasinghe JP, Mercado J, Brinster LR, Butman JA, Lonser RR, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M Cancer Research. 71: 2417-2417. DOI: 10.1158/1538-7445.Am2011-2417 |
0.338 |
|
| 2010 |
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prevention Research (Philadelphia, Pa.). 3: 1066-76. PMID 20810672 DOI: 10.1158/1940-6207.CAPR-10-0055 |
0.478 |
|
| 2010 |
Memmott RM, Dennis PA. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4-10. PMID 20028747 DOI: 10.1158/1078-0432.CCR-09-0234 |
0.527 |
|
| 2010 |
Gills JJ, Morrow B, Kawabata S, Mercado J, Hennessy B, Kunnumakkara AB, Pao W, Dennis PA. Abstract 624: Synergistic effects of combining the Akt inhibitor triciribine with erlotinib in EGFR TKI-resistant NSCLC Cancer Research. 70: 624-624. DOI: 10.1158/1538-7445.Am10-624 |
0.428 |
|
| 2009 |
Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prevention Research (Philadelphia, Pa.). 2: 370-6. PMID 19336734 DOI: 10.1158/1940-6207.CAPR-08-0209 |
0.338 |
|
| 2009 |
Granville CA, Memmott RM, Balogh A, Mariotti J, Kawabata S, Han W, Lopiccolo J, Foley J, Liewehr DJ, Steinberg SM, Fowler DH, Hollander MC, Dennis PA. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. Plos One. 4: e5061. PMID 19330036 DOI: 10.1371/journal.pone.0005061 |
0.324 |
|
| 2009 |
Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Current Oncology Reports. 11: 102-10. PMID 19216841 DOI: 10.1007/s11912-009-0016-4 |
0.406 |
|
| 2009 |
Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cellular Signalling. 21: 656-64. PMID 19166931 DOI: 10.1016/j.cellsig.2009.01.004 |
0.379 |
|
| 2008 |
Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Research. 68: 580-8. PMID 18199555 DOI: 10.1158/0008-5472.CAN-07-3091 |
0.476 |
|
| 2008 |
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 11: 32-50. PMID 18166498 DOI: 10.1016/j.drup.2007.11.003 |
0.382 |
|
| 2008 |
Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy. 4: 107-9. PMID 18000394 DOI: 10.4161/auto.5224 |
0.343 |
|
| 2007 |
LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anti-Cancer Drugs. 18: 861-74. PMID 17667591 DOI: 10.1097/CAD.0b013e3280cc2c6f |
0.415 |
|
| 2007 |
Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel N, Han J, Kozikowski AP, Dennis PA. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38α, through MKK3/6-independent and -dependent mechanisms Journal of Biological Chemistry. 282: 27020-27029. PMID 17631503 DOI: 10.1074/Jbc.M701108200 |
0.37 |
|
| 2007 |
Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2281-9. PMID 17404113 DOI: 10.1158/1078-0432.Ccr-06-2570 |
0.458 |
|
| 2007 |
Lipkowitz S, Dennis PA. PPARγ agonists follow an unknown TRAIL in lung cancer Cancer Biology and Therapy. 6: 107-109. PMID 17224637 |
0.394 |
|
| 2007 |
Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J, Soda H, Kohno S, Egilsson V, Dennis PA. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (Amsterdam, Netherlands). 55: 115-21. PMID 17097759 DOI: 10.1016/j.lungcan.2006.09.026 |
0.356 |
|
| 2007 |
Dennis PA, Kastan MB. Cellular survival pathways and resistance to cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 1: 301-9. PMID 17092811 DOI: 10.1016/S1368-7646(98)80046-0 |
0.311 |
|
| 2006 |
Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3502-9. PMID 16740776 DOI: 10.1158/1078-0432.Ccr-05-1837 |
0.33 |
|
| 2006 |
Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt Molecular Cancer Therapeutics. 5: 713-722. PMID 16546986 DOI: 10.1158/1535-7163.Mct-05-0484 |
0.414 |
|
| 2006 |
Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 679-89. PMID 16467077 DOI: 10.1158/1078-0432.CCR-05-1654 |
0.371 |
|
| 2006 |
Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet (London, England). 367: 300. PMID 16443034 DOI: 10.1016/S0140-6736(06)68064-1 |
0.445 |
|
| 2006 |
Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors Journal of Clinical Oncology. 24: 306-314. PMID 16330671 DOI: 10.1200/JCO.2005.02.4133 |
0.414 |
|
| 2005 |
Ballas MS, Dennis PA. A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Cancer Biology & Therapy. 4: 1316-7. PMID 16434876 DOI: 10.4161/cbt.4.12.2488 |
0.427 |
|
| 2005 |
Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Research. 65: 8423-32. PMID 16166321 DOI: 10.1158/0008-5472.Can-05-0058 |
0.431 |
|
| 2005 |
Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 26: 1182-95. PMID 15790591 DOI: 10.1093/Carcin/Bgi072 |
0.461 |
|
| 2005 |
Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death Cancer Research. 65: 2070-2075. PMID 15781614 DOI: 10.1158/0008-5472.CAN-04-3606 |
0.378 |
|
| 2005 |
Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. American Journal of Respiratory Cell and Molecular Biology. 32: 169-76. PMID 15713815 DOI: 10.1165/rcmb.F290 |
0.394 |
|
| 2004 |
Tsurutani J, Dennis PA. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. 96: 1795; author reply 1. PMID 15572763 DOI: 10.1093/jnci/djh342 |
0.469 |
|
| 2004 |
Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opinion On Investigational Drugs. 13: 787-97. PMID 15212619 DOI: 10.1517/13543784.13.7.787 |
0.351 |
|
| 2004 |
West KA, Linnoila IR, Brognard J, Belinsky S, Harris C, Dennis PA. Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest. 125: 101S-2S. PMID 15136436 DOI: 10.1378/Chest.125.5_Suppl.101S |
0.468 |
|
| 2004 |
Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA. Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues Cancer Research. 64: 2782-2792. PMID 15087394 DOI: 10.1158/0008-5472.Can-03-1530 |
0.366 |
|
| 2004 |
Gills JJ, Granville CA, Dennis PA. Targeting aberrant signal transduction pathways in lung cancer. Cancer Biology & Therapy. 3: 147-55. PMID 14764993 DOI: 10.4161/cbt.3.2.612 |
0.453 |
|
| 2004 |
West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Research. 64: 446-51. PMID 14744754 DOI: 10.1158/0008-5472.CAN-03-3241 |
0.587 |
|
| 2003 |
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22: 2812-22. PMID 12743604 DOI: 10.1038/Sj.Onc.1206388 |
0.388 |
|
| 2003 |
Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Research. 63: 780-6. PMID 12591726 |
0.513 |
|
| 2003 |
Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt Journal of the American Chemical Society. 125: 1144-1145. PMID 12553797 DOI: 10.1021/Ja0285159 |
0.35 |
|
| 2003 |
West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. The Journal of Clinical Investigation. 111: 81-90. PMID 12511591 DOI: 10.1172/Jci16147 |
0.538 |
|
| 2002 |
West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 5: 234-48. PMID 12531180 DOI: 10.1016/S1368-7646(02)00120-6 |
0.4 |
|
| 2002 |
Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics. 1: 707-17. PMID 12479367 |
0.367 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2007 |
Lopiccolo J, Ballas MS, Dennis PA. PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Critical Reviews in Oncology/Hematology. 63: 203-14. PMID 17643312 DOI: 10.1016/j.critrevonc.2007.06.002 |
0.299 |
|
| 2008 |
Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR, Dennis PA. Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia (New York, N.Y.). 10: 866-72. PMID 18683321 |
0.297 |
|
| 2005 |
Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR, Kaye FJ. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes Cancer Research. 65: 7137-7144. PMID 16103063 DOI: 10.1158/0008-5472.Can-05-1125 |
0.296 |
|
| 2013 |
Kitagawa H, Cataisson C, Handisurya A, Day PM, Yuspa SH, Dennis PA. Abstract 1081: Rapamycin is a chemopreventive and chemotherapeutic agent for ras-driven epidermal squamous cell carcinoma: evidence from mouse models. Cancer Research. 73: 1081-1081. DOI: 10.1158/1538-7445.Am2013-1081 |
0.295 |
|
| 2010 |
Blumenthal GM, Ballas MS, Bernstein W, Shamloo BK, Root H, Helsabeck C, Chun G, Figg WD, Giaccone G, Dennis PA. A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. Journal of Clinical Oncology. 28: 7600-7600. DOI: 10.1200/Jco.2010.28.15_Suppl.7600 |
0.289 |
|
| 2020 |
Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Boothman AM, ... ... Dennis PA, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32209338 DOI: 10.1016/j.annonc.2020.03.287 |
0.287 |
|
| 2008 |
Dennis PA. Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls Aacr Education Book. 2008: 25-35. DOI: 10.1158/AACR.EDB-08-8183 |
0.284 |
|
| 2019 |
Gutierrez E, Cahatol I, Bailey CAR, Lafargue A, Zhang N, Song Y, Tian H, Zhang Y, Chan R, Gu K, Zhang ACC, Tang J, Liu C, Connis N, Dennis P, et al. Regulation of RhoB Gene Expression during Tumorigenesis and Aging Process and Its Potential Applications in These Processes. Cancers. 11. PMID 31200451 DOI: 10.3390/cancers11060818 |
0.284 |
|
| 2015 |
Kawabata S, Hollander MC, Munasinghe JP, Brinster LR, Mercado-Matos JR, Li J, Regales L, Pao W, Jänne PA, Wong KK, Butman JA, Lonser RR, Hansen MR, Gurgel RK, Vortmeyer AO, ... Dennis PA, et al. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget. 6: 11357-68. PMID 26027747 DOI: 10.18632/Oncotarget.3605 |
0.282 |
|
| 2005 |
Dennis PA, Van Waes C, Gutkind JS, Kellar KJ, Vinson C, Mukhin AG, Spitz MR, Bailey-Wilson JE, Yeh GC, Anderson LM, Wiest JS. The biology of tobacco and nicotine: bench to bedside. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 764-7. PMID 15824140 DOI: 10.1158/1055-9965.Epi-04-0652 |
0.282 |
|
| 2005 |
Fiala ES, Sohn OS, Wang CX, Seibert E, Tsurutani J, Dennis PA, El-Bayoumy K, Sodum RS, Desai D, Reinhardt J, Aliaga C. Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. Carcinogenesis. 26: 605-12. PMID 15579485 DOI: 10.1093/Carcin/Bgh341 |
0.28 |
|
| 2015 |
Kawabata S, Heredia A, Gills J, Redfield RR, Dennis PA, Bryant J. Impact of HIV on lung tumorigenesis in an animal model. Aids (London, England). 29: 633-5. PMID 25611150 DOI: 10.1097/QAD.0000000000000588 |
0.275 |
|
| 2003 |
Lorenzo PS, Dennis PA. Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 6: 329-39. PMID 14744497 |
0.274 |
|
| 2017 |
Von Pawel J, Vynnychenko I, Jiang H, Huang Y, Dennis PA. A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC. Journal of Clinical Oncology. 35: TPS8585-TPS8585. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS8585 |
0.272 |
|
| 2021 |
Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, Meekin J, Griffin M, Bisha I, Proia TA, ... ... Dennis PA, et al. Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown. Cancer Discovery. PMID 34230008 DOI: 10.1158/2159-8290.CD-20-1543 |
0.272 |
|
| 2008 |
Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Current Opinion in Hiv and Aids. 3: 666-75. PMID 19373040 DOI: 10.1097/COH.0b013e328313915d |
0.267 |
|
| 2003 |
Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. The Journal of Experimental Medicine. 198: 1337-47. PMID 14581607 DOI: 10.1084/Jem.20030593 |
0.266 |
|
| 2006 |
Tsurutani J, Ballas MS, Dennis PA. Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1963; author reply 1. PMID 16622278 DOI: 10.1200/JCO.2005.05.1318 |
0.256 |
|
| 2017 |
Garassino M, Cho B, Gray J, Mazières J, Park K, Soo R, Dennis P, Huang Y, Wadsworth C, Rizvi N. Durvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study Annals of Oncology. 28: ii28-ii29. DOI: 10.1093/ANNONC/MDX091.002 |
0.256 |
|
| 2020 |
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Jaime JC, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Poole L, ... ... Dennis PA, et al. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer (Amsterdam, Netherlands). 147: 137-142. PMID 32702570 DOI: 10.1016/j.lungcan.2020.06.032 |
0.249 |
|
| 2017 |
Garassino M, Vansteenkiste J, Kim J, Léna H, Mazières J, Powderly J, Dennis P, Huang Y, Wadsworth C, Rizvi N. PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study Journal of Thoracic Oncology. 12: S10-S11. DOI: 10.1016/J.JTHO.2016.11.012 |
0.248 |
|
| 2020 |
Juergens RA, Hao D, Ellis PM, Tu D, Mates M, Kollmannsberger C, Bradbury PA, Tehfe M, Wheatley-Price P, Robinson A, Bebb G, Laskin J, Goffin J, Hilton J, Tomiak A, ... ... Dennis PA, et al. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer (Amsterdam, Netherlands). 143: 1-11. PMID 32169783 DOI: 10.1016/J.Lungcan.2020.02.016 |
0.247 |
|
| 2021 |
Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Langer C, Senan S, Spigel D, Rydén A, Zhang Y, ... ... Dennis PA, et al. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer. Future Oncology (London, England). PMID 33583206 DOI: 10.2217/fon-2020-1102 |
0.246 |
|
| 2013 |
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology and Metabolism: Tem. 24: 469-80. PMID 23773243 DOI: 10.1016/j.tem.2013.05.004 |
0.244 |
|
| 2012 |
Tzarum N, Eisenberg-Domovich Y, Gills JJ, Dennis PA, Livnah O. Lipid molecules induce p38α activation via a novel molecular switch. Journal of Molecular Biology. 424: 339-53. PMID 23079240 DOI: 10.1016/j.jmb.2012.10.007 |
0.24 |
|
| 2018 |
Raja R, Kuziora M, Brohawn P, Higgs BW, Gupta A, Dennis PA, Ranade K. Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30093454 DOI: 10.1158/1078-0432.CCR-18-0386 |
0.239 |
|
| 2014 |
Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G, Helsabeck C, Steinberg SM, LoPiccolo J, Kawabata S, Gardner ER, Figg WD, ... Dennis PA, et al. A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget. 5: 8161-72. PMID 25327558 DOI: 10.18632/Oncotarget.2415 |
0.238 |
|
| 2009 |
Dennis PA. Rapamycin for chemoprevention of upper aerodigestive tract cancers. Cancer Prevention Research (Philadelphia, Pa.). 2: 7-9. PMID 19139011 DOI: 10.1158/1940-6207.CAPR-08-0215 |
0.237 |
|
| 2017 |
Paz-Ares LG, Jiang H, Huang Y, Dennis PA. A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian. Journal of Clinical Oncology. 35: TPS8586-TPS8586. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS8586 |
0.233 |
|
| 2008 |
Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. European Journal of Human Genetics : Ejhg. 16: 1289-300. PMID 18781191 DOI: 10.1038/ejhg.2008.162 |
0.232 |
|
| 2017 |
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis PA, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 28885881 DOI: 10.1056/NEJMoa1709937 |
0.23 |
|
| 2006 |
O'Mahony D, Dennis PA. Using immunotherapy to target EGF in patients with NSCLC. Cancer Biology & Therapy. 5: 150-1. PMID 16552172 DOI: 10.4161/cbt.5.2.2557 |
0.225 |
|
| 2017 |
Paz-Ares LG, Shen K, Higgs BW, Morehouse C, Rizvi NA, Segal NH, Jin X, Zheng Y, Narwal R, Gupta AK, Dennis PA, Mukhopadhyay P, Ranade K. Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials. Journal of Clinical Oncology. 35: 3038-3038. DOI: 10.1200/JCO.2017.35.15_SUPPL.3038 |
0.223 |
|
| 2011 |
Kunnumakkara AB, Memmott RM, Maier CR, Kawabata S, Quinn B, Gills J, Dallos M, Hollander CM, Dennis PA. Abstract 614: Efficacy of metformin in two mouse models of Li-Fraumeni syndrome Cancer Research. 71: 614-614. DOI: 10.1158/1538-7445.Am2011-614 |
0.221 |
|
| 2007 |
Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, ... Dennis PA, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5183-94. PMID 17785575 DOI: 10.1158/1078-0432.Ccr-07-0161 |
0.221 |
|
| 2004 |
Dennis PA. Disparities in cancer funding. Science (New York, N.Y.). 305: 1401-2. PMID 15353780 DOI: 10.1126/science.305.5689.1401e |
0.218 |
|
| 2018 |
Garassino MC, Cho BC, Kim J, Mazieres J, Gray JE, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA. Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study. Journal of Clinical Oncology. 36: 9058-9058. DOI: 10.1200/JCO.2018.36.15_SUPPL.9058 |
0.214 |
|
| 2018 |
Jure-Kunkel M, Wu S, Xiao F, Abdullah SE, Gao G, Englert JM, Hsieh H, Mukhopadhyay P, Gupta AK, Dennis PA, Higgs BW, Ranade K. Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC. Journal of Clinical Oncology. 36: 3028-3028. DOI: 10.1200/JCO.2018.36.15_suppl.3028 |
0.211 |
|
| 2011 |
Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews. Cancer. 11: 289-301. PMID 21430697 DOI: 10.1038/nrc3037 |
0.206 |
|
| 2008 |
Granville CA, Memmott RM, Gills JJ, Dennis PA. Targeting the Phosphoinositide-3-kinase/Akt/Mammalian Target of Rapamycin Pathway Apoptosis and Cancer Therapy: From Cutting-Edge Science to Novel Therapeutic Concepts. 2: 966-996. DOI: 10.1002/9783527619665.ch38 |
0.205 |
|
| 2017 |
Zheng Y, Narwal R, Jin C, Wang B, Jin X, Mukhopadhyay P, Higgs BW, Gupta AK, Dennis PA, Roskos L. Tumor kinetic modeling and identification of predictive factors for tumor response to durvalumab in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: 11555-11555. DOI: 10.1200/JCO.2017.35.15_SUPPL.11555 |
0.203 |
|
| 2020 |
Ye J, Ji X, Dennis PA, Abdullah H, Mukhopadhyay P. Correlations Between Progression-free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-analysis. Clinical Pharmacology and Therapeutics. PMID 32564368 DOI: 10.1002/cpt.1956 |
0.202 |
|
| 2020 |
Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discovery. PMID 32816849 DOI: 10.1158/2159-8290.CD-20-0047 |
0.199 |
|
| 2017 |
Vynnychenko I, Jiang H, Huang Y, Dennis P, Von Pawel J. P2.04-001 BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC Journal of Thoracic Oncology. 12: S2397-S2398. DOI: 10.1016/J.JTHO.2017.11.014 |
0.197 |
|
| 2017 |
Zhang X, Park K, Rizvi N, Dennis P, Narwal R, Huang Y, Arani R, Mukhopadhyay P. Prediction of survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments Annals of Oncology. 28: v467-v468. DOI: 10.1093/annonc/mdx380.015 |
0.192 |
|
| 2017 |
Murakami S, Özgüroğlu M, Villegas A, Daniel D, Baz D, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis P, et al. PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC Annals of Oncology. 28: x122. DOI: 10.1093/annonc/mdx670 |
0.187 |
|
| 2009 |
Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabeck C, Root H, Figg WD, Bernstein W. A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2583. PMID 27961900 DOI: 10.1200/Jco.2009.27.15_Suppl.2583 |
0.186 |
|
| 1990 |
Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P. Growth factor control of extracellular proteolysis. Cell Differentiation and Development : the Official Journal of the International Society of Developmental Biologists. 32: 313-8. PMID 1711916 DOI: 10.1016/0922-3371(90)90045-X |
0.185 |
|
| 2020 |
Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, et al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer (Amsterdam, Netherlands). 151: 30-38. PMID 33285469 DOI: 10.1016/j.lungcan.2020.11.024 |
0.185 |
|
| 2019 |
Wu Y, Wang L, Sendur M, Kim Y, Zhu Z, Cheng Y, Li P, Qin Y, Macpherson E, Dennis P, Lu S. PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC Annals of Oncology. 30: ix113-ix114. DOI: 10.1093/annonc/mdz438.021 |
0.184 |
|
| 2017 |
Mok T, Johnson M, Garon E, Peters S, Soria J, Wang L, Jarkowski A, Dennis P, Zhou C. P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC Journal of Thoracic Oncology. 12: S1975. DOI: 10.1016/J.JTHO.2017.09.867 |
0.184 |
|
| 2014 |
Kalu NN, Desai PJ, Shirley CM, Gibson W, Dennis PA, Ambinder RF. Nelfinavir inhibits maturation and export of herpes simplex virus 1. Journal of Virology. 88: 5455-61. PMID 24574416 DOI: 10.1128/Jvi.03790-13 |
0.183 |
|
| 2018 |
Antonia SJ, Hellmann MD, Dennis PA, Melillo G, Abdullah SE, Lloyd A, Rizvi NA. A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies. Journal of Clinical Oncology. 36: 8556-8556. DOI: 10.1200/JCO.2018.36.15_SUPPL.8556 |
0.182 |
|
| 2019 |
Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, ... ... Dennis PA, et al. Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31622733 DOI: 10.1016/j.jtho.2019.10.002 |
0.18 |
|
| 2001 |
Kastanos EK, Zajac-Kaye M, Dennis PA, Allegra CJ. Downregulation of p21/WAF1 expression by thymidylate synthase. Biochemical and Biophysical Research Communications. 285: 195-200. PMID 11444825 DOI: 10.1006/BBRC.2001.5145 |
0.176 |
|
| 2017 |
Paz-Ares L, Villegas A, Daniel D, Baz D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis P, et al. PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC Annals of Oncology. 28: v634. DOI: 10.1093/ANNONC/MDX440.049 |
0.176 |
|
| 2018 |
Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H, Corral J, Gray J, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo R, Huang Y, ... ... Dennis P, et al. P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC Journal of Thoracic Oncology. 13: S467-S468. DOI: 10.1016/J.JTHO.2018.08.577 |
0.176 |
|
| 2017 |
Powles T, Jin C, Zheng Y, Baverel P, Narwal R, Mukhopadhyay P, Jin X, Dennis PA, Gupta AK, Ben Y, Ho TW, Roskos L. Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab. Journal of Clinical Oncology. 35: 3035-3035. DOI: 10.1200/JCO.2017.35.15_SUPPL.3035 |
0.176 |
|
| 2020 |
Gopalakrishnan V, Weiner B, Ford C, Sellman B, Hammond S, Freeman D, Dennis P, Soria J, Wortman J, Henn M. Intervention strategies for microbial therapeutics in cancer immunotherapy Immuno-Oncology Technology. 6: 9-17. DOI: 10.1016/j.iotech.2020.05.001 |
0.172 |
|
| 2021 |
Peters S, Spigel D, Ahn M, Tsuboi M, Chaft J, Harpole D, Goss G, Barlesi F, Abbosh C, Poole L, May R, Dennis P, Swanton C. P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery Journal of Thoracic Oncology. 16: S258-S259. DOI: 10.1016/J.JTHO.2021.01.376 |
0.169 |
|
| 2019 |
Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, Sharpe A, Rizvi NA, Garassino MC, Walker J. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell PD-L1 Expression in Patients with Advanced NCSLC Screened for the ATLANTIC Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31063864 DOI: 10.1016/j.jtho.2019.04.025 |
0.169 |
|
| 1991 |
Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proceedings of the National Academy of Sciences of the United States of America. 88: 580-4. PMID 1846448 DOI: 10.1073/PNAS.88.2.580 |
0.168 |
|
| 2017 |
Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, Vicini P, Roskos L, Narwal R. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status. Clinical Pharmacology and Therapeutics. PMID 29243223 DOI: 10.1002/Cpt.982 |
0.167 |
|
| 2005 |
Dennis P, Tsurutani J, Fukuoka J, Tsurutani H, Shih J, Hewitt S, Jen J. P-607 Evaluation of two phosphorylation sites establishes Aktactivation as a poor prognostic factor for all stages of NSCLC tumors Lung Cancer. 49: S278. DOI: 10.1016/S0169-5002(05)81100-6 |
0.165 |
|
| 2011 |
Hollander MC, Blumenthal GM, Dennis PA. Erratum: PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nature Reviews Cancer. 11: 458-458. DOI: 10.1038/NRC3085 |
0.163 |
|
| 2017 |
Hui R, Özgüroğlu M, Daniel D, Baz D, Murakami S, Yokoi T, Chiappori A, Lee K, De Wit M, Cho BC, Gray J, Rydén A, Viviers L, Poole L, Dennis P, et al. PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC Journal of Thoracic Oncology. 12: S1604. DOI: 10.1016/J.JTHO.2017.09.096 |
0.163 |
|
| 2011 |
West KA, Dennis PA. Starting with the ABCs: Akt in breast cancer Molecular Cancer Therapeutics. 10: 2031. PMID 22072813 DOI: 10.1158/1535-7163.MCT-11-0712 |
0.162 |
|
| 2008 |
Blumenthal GM, Dennis PA. Germline PTEN mutations as a cause of early-onset endometrial cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2234; author reply 2. PMID 18445858 DOI: 10.1200/JCO.2007.15.8949 |
0.162 |
|
| 2019 |
Planchard D, Cho BC, Gray JE, Paz-Ares LG, Ozguroglu M, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, De Wit M, Gu Y, ... ... Dennis PA, et al. First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC. Journal of Clinical Oncology. 37: 9054-9054. DOI: 10.1200/JCO.2019.37.15_SUPPL.9054 |
0.157 |
|
| 2013 |
Kalin A, Merideth MA, Regier DS, Blumenthal GM, Dennis PA, Stratton P. Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. Obstetrics and Gynecology. 121: 461-4. PMID 23344409 DOI: http://10 1097/AOG.0b013e318270444f |
0.15 |
|
| 2013 |
Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM. Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. The Journal of Urology. 190: 1990-8. PMID 23764071 DOI: 10.1016/J.Juro.2013.06.012 |
0.149 |
|
| 2017 |
Jin C, Zheng Y, Jin X, Mukhopadhyay P, Gupta AK, Dennis PA, Ben Y, Roskos L, Narwal R. Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors. Journal of Clinical Oncology. 35: 2568-2568. DOI: 10.1200/JCO.2017.35.15_SUPPL.2568 |
0.148 |
|
| 2017 |
Baverel P, Dubois V, Jin C, Song X, Jin X, Mukhopadhyay P, Gupta AK, Dennis PA, Ben Y, Roskos L, Narwal R. Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors. Journal of Clinical Oncology. 35: 2566-2566. DOI: 10.1200/JCO.2017.35.15_SUPPL.2566 |
0.148 |
|
| 2019 |
Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, Hornyak TJ, Wank S, Hewitt SM, Morrow B, Memmott RM, Rajan A, Dennis PA. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in . The Oncologist. PMID 31350329 DOI: 10.1634/Theoncologist.2019-0514 |
0.141 |
|
| 1998 |
Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB, Kumar CC. Human smooth muscle α-actin gene is a transcriptional target of the p53 tumor suppressor protein Oncogene. 16: 1299-1308. PMID 9546431 DOI: 10.1038/sj.onc.1201645 |
0.141 |
|
| 2009 |
Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e226; author reply e. PMID 19858366 DOI: 10.1200/JCO.2009.25.3963 |
0.134 |
|
| 2019 |
Gray JE, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares LG, Faivre-Finn C, Vansteenkiste JF, Spigel DR, ... ... Dennis PA, et al. Three-year overall survival update from the PACIFIC trial. Journal of Clinical Oncology. 37: 8526-8526. DOI: 10.1200/JCO.2019.37.15_SUPPL.8526 |
0.134 |
|
| 2019 |
Hellmann MD, Zhang Q, Abdullah SE, Chaft JE, Segal NH, Gao C, Dennis PA, Higgs BW. Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease. Journal of Clinical Oncology. 37: 2546-2546. DOI: 10.1200/JCO.2019.37.15_SUPPL.2546 |
0.133 |
|
| 2017 |
Paz-Ares L, Jiang H, Huang Y, Dennis P. P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC Journal of Thoracic Oncology. 12: S2398. DOI: 10.1016/J.JTHO.2017.11.015 |
0.129 |
|
| 2013 |
Komiya T, Blumenthal GM, Ballas MS, Dechowdhury R, Manu M, Fioravanti S, Hornyak TJ, Wank S, Weinstein D, Morris J, Hewitt SM, Memmott R, Dennis PA, Morrow B. A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN. Journal of Clinical Oncology. 31: 2532-2532. DOI: 10.1200/JCO.2013.31.15_SUPPL.2532 |
0.128 |
|
| 2012 |
Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, ... ... Dennis PA, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genetics. 205: 479-87. PMID 22939227 DOI: 10.1016/J.Cancergen.2012.06.008 |
0.127 |
|
| 2018 |
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, Dennis P, Antonia S. 233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes Journal of Thoracic Oncology. 13: S71. DOI: 10.1016/S1556-0864(18)30401-5 |
0.125 |
|
| 2016 |
Janne PA, Ghiorghiu DC, Smith PD, Belli R, Dennis PA, Mariani GL. SELECT-4: Phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. Journal of Clinical Oncology. 34: TPS2607-TPS2607. DOI: 10.1200/JCO.2016.34.15_SUPPL.TPS2607 |
0.122 |
|
| 2013 |
Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M. Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clinical Lung Cancer. 14: 452-6. PMID 23540867 DOI: 10.1016/j.cllc.2013.01.005 |
0.114 |
|
| 1984 |
Dennis PA, Aronson NN. Uptake and degradation of 125I-labeled rat asialoorosomucoid by the perfused rat liver. Biochimica Et Biophysica Acta. 798: 14-20. PMID 6704419 DOI: 10.1016/0304-4165(84)90004-7 |
0.113 |
|
| 1990 |
Dennis PA, Rifkin DB. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. Journal of Cellular Physiology. 144: 84-98. PMID 2195045 DOI: 10.1002/JCP.1041440112 |
0.107 |
|
| 2018 |
Kuziora M, Si H, Higgs B, Brohawn P, Streicher K, Jure-Kunkel M, Raja R, Helman E, Franovic A, Cooper Z, Shrestha Y, Holoweckyj N, Lee Y, Achour I, Ye J, ... ... Dennis P, et al. Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types Annals of Oncology. 29: x1. DOI: 10.1093/ANNONC/MDY493.001 |
0.103 |
|
| 2020 |
Bauman J, Karam S, Nishio M, Ahn M, Kim D, Kim S, Murakami H, Wang L, Shetty J, Wu K, Dennis P, Cho B. 1056P Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study Annals of Oncology. 31: S721-S722. DOI: 10.1016/j.annonc.2020.08.1176 |
0.09 |
|
| 1988 |
Brock TA, Dennis PA, Griendling KK, Diehl TS, Davies PF. GTP gamma S loading of endothelial cells stimulates phospholipase C and uncouples ATP receptors. The American Journal of Physiology. 255: C667-73. PMID 3056027 DOI: 10.1152/Ajpcell.1988.255.5.C667 |
0.083 |
|
| 2008 |
Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, ... ... Dennis PB, ... ... Dennis PA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 4: 151-75. PMID 18188003 DOI: 10.4161/Auto.5338 |
0.082 |
|
| 2018 |
Faivre-Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, ... Dennis PA, et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii488. PMID 32137260 DOI: 10.1093/annonc/mdy291 |
0.071 |
|
| 1985 |
Dennis PA, Aronson NN. Metabolism of [3H]leupeptin by rat liver. Archives of Biochemistry and Biophysics. 240: 768-76. PMID 4026303 DOI: 10.1016/0003-9861(85)90085-2 |
0.071 |
|
| 2020 |
Naidoo J, Vansteenkiste JF, Faivre-Finn C, Özgüroğlu M, Murakami S, Hui R, Quantin X, Broadhurst H, Newton M, Dennis PA, Antonia SJ. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC). Journal of Clinical Oncology. 38: 9048-9048. DOI: 10.1200/jco.2020.38.15_suppl.9048 |
0.061 |
|
| 2020 |
Gopalakrishnan V, Sellman BR, Cohen TS, Dennis PA. Antibiotics and Immunotherapy: Too Much of Anything is Bad! European Urology. PMID 32811714 DOI: 10.1016/j.eururo.2020.07.027 |
0.049 |
|
| 1982 |
Dennis PA, Aronson NN. The effects of low temperature and chloroquine on 125I-insulin degradation by the perfused rat liver. Archives of Biochemistry and Biophysics. 212: 170-6. PMID 7030218 DOI: 10.1016/0003-9861(81)90356-8 |
0.029 |
|
| Hide low-probability matches. |